Information Provided By: 
Fly News Breaks for March 7, 2017
OCX, CDNA, VCYT, FMI
Mar 7, 2017 | 07:50 EDT
Janney Capital analyst Paul Knight upgraded Foundation Medicine (FMI) to Neutral from Sell, citing "easy" earnings comparisons in Q1 and low expectations. In his upgrade note, Knight added that if Foundation's recent rebound is due to a change in sector perception, then he views Veracyte (VCYT), CaredDx (CDNA), and Oncocyte (OCX) as having "more catalysts, more revenue visibility, and better value" and sees all three as undervaled.
News For FMI;VCYT;CDNA;OCX From the Last 2 Days
There are no results for your query FMI;VCYT;CDNA;OCX
